VOLUME 19 NUMBER 1 • July 2022 3 SA JOURNAL OF DIABETES & VASCULAR DISEASE From the Editor’s Desk From the Editor’s Desk Correspondence to: FA Mahomed Head of Internal Medicine, Madadeni Hospital Newcastle, KwaZulu-Natal Tladi and colleagues (page 4) studied metabolic syndrome features in a Batswana population. They found young patients and females were risk groups to watch out for. This is compatible with other data coming from Botswana.1 This may forebode higher future rates of hypertension, diabetes and cardiovascular disease in Botswana. This is useful information for the Botswana government health authorities, to help with prevention strategies and health-resource allocation. Mokwena and Modjaji, from Garankuwa, discuss an interesting set of patients in informal settlements, from a metabolic syndrome viewpoint (page 10). They found striking rates of hypertension and obesity. This group of patients may fall outside the usual public health surveillance net and may be an important group to identify in future surveys, especially when it comes to health planning and budget allocation.2 There are also comments on the American Diabetes Association Standards of Medical Care, new stem cell research in looking for American Diabetes Association updates its Standards of Medical Care for 2022 The American Diabetes Association (ADA) updated its Standards of Medical Care supplement in December, to provide clinicians, researchers, policy makers and other interested individuals with the components of diabetes care, general treatment goals and tools to evaluate the quality of care. Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycaemic control. Ongoing self-management education and support are critical to preventing acute complications and reducing the risk of long-term complications. Significant evidence exists that supports a range of interventions to improve diabetes outcomes. The Standards of Care recommendations should be applied in the context of excellent clinical care, with adjustments for individual preferences, co-morbidities and other patient factors. The recommendations include screening, diagnostic and therapeutic actions that are known or believed to favourably affect health outcomes of patients with diabetes. They encompass care for youth (from birth to 11 years and adolescents aged 12–18 years) and older adults (65 years and older). The ADA has been actively involved in the development and dissemination of diabetes care clinical practice recommendations and related documents for more than 30 years and its Standards of Medical Care is viewed as an important resource for those caring for people with diabetes. The annual Standards of Care supplement to Diabetes Care contains official ADA position, is authored by the ADA and provides all of the ADA’s current clinical practice recommendations. The Standards of Medical Care in Diabetes was originally approved in 1988. Source: MedicalBrief 2022 CUSTOMER CARE LINE +27 21 707 7000 www.mydynami cs.co.za CALSAR 5/80 mg, 5/160 mg, 10/160 mg. Each tablet contains amlodipine/valsartan 5/80 mg, 5/160 mg, 10/160 mg respectively. S3 A51/7.1.3/1106, 1107, 1108. For full prescribing information, refer to the professional information approved by SAHPRA, March 2021. CRA928/05/2022. | | | DILIGENT WORKERS BIOEQUIVALENT TO THE ORIGINATOR VALSARTAN/AMLODIPINE CONVENIENTLY PACKED IN 30 TABLETS a cure for type 1 diabetes and some interesting information about verapamil (old drug, new tricks). References 1. Maruapula SD, Jackson JC, Holsten J, Shaibu S, Malete L, Wrotniak B, et al. Socioeconomic status and urbanization are linked to snacks and obesity in adolescents in Botswana. Public Health Nutr 2011; 14(12), 2260–2267. 2. Atun R, Davies J, Gale EAM, Bärnighausen T, Beran D, Kengne AP, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol Commiss 2017; 5(8): 622–667.
RkJQdWJsaXNoZXIy NDIzNzc=